In Brief: Zeneca Zomig
Executive Summary
Zeneca Zomig: NDA filed Nov. 26 for zolmitriptan, a second-generation selective serotonin antagonist, for the acute treatment of migraine, company announces Jan. 16. The Zomig NDA is supported by eight clinical trials involving more than 2,700 patients...